Citigroup Reaffirms Buy Rating for Insulet (NASDAQ:PODD)
Insulet (NASDAQ:PODD – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at Citigroup in a research note issued on Thursday, MarketBeat.com reports. They currently have a $380.00 target price on the medical instruments supplier’s stock, up from their previous target price of $320.00. Citigroup’s target price indicates a potential upside of […]
Insulet (NASDAQ:PODD – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at Citigroup in a research note issued on Thursday, MarketBeat.com reports. They currently have a $380.00 target price on the medical instruments supplier’s stock, up from their previous target price of $320.00. Citigroup’s target price indicates a potential upside of […]
